

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

SCHEDULE 13D

**Under the Securities Exchange Act of 1934
(Amendment No. 4)***

Aileron Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share
(Title of Class of Securities)

00887A 105

(CUSIP Number)

Bart Dzikowski

Secretary of the Board

Novartis Bioventures Ltd.

Lichtstrasse 35

CH-4056 Basel, Switzerland

+41 61 324 3714

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

March 17, 2020

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of section 18 of the Securities Exchange Act of 1934, as amended ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names of reporting persons	Novartis Bioventures Ltd.
2.	Check the appropriate box if a member of a group	(a) <input type="radio"/> (b) <input type="radio"/>
3.	SEC use only	
4.	Source of funds (see instructions)	WC
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	<input type="radio"/>
6.	Citizenship or place of organization	Switzerland
Number of shares beneficially owned by each reporting person with:		
7.	Sole voting power	0
8.	Shared voting power	1,882,119
9.	Sole dispositive power	0
10.	Shared dispositive power	1,882,119
11.	Aggregate amount beneficially owned by each reporting person	1,882,119
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions)	<input type="radio"/>
13.	Percent of class represented by amount in Row (11)	6.77% (1)
14.	Type of reporting person (see instructions)	CO

(1) Based on 27,810,358 shares of Common Stock outstanding as of November 5, 2019, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 7, 2019.

1.	Names of reporting persons	Novartis AG
2.	Check the appropriate box if a member of a group	(a) <input type="radio"/> (b) <input type="radio"/>
3.	SEC use only	
4.	Source of funds (see instructions)	WC
5.	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	<input type="radio"/>
6.	Citizenship or place of organization	Switzerland
Number of shares beneficially owned by each reporting person with:		
7.	Sole voting power	0
8.	Shared voting power	1,882,119
9.	Sole dispositive power	0
10.	Shared dispositive power	1,882,119
11.	Aggregate amount beneficially owned by each reporting person	1,882,119
12.	Check if the aggregate amount in Row (11) excludes certain shares (see instructions)	<input type="radio"/>
13.	Percent of class represented by amount in Row (11)	6.77% (1)
14.	Type of reporting person (see instructions)	CO

(1) Based on 27,810,358 shares of Common Stock outstanding as of November 5, 2019 as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on November 7, 2019.

Item 1. Security and Issuer.

This Amendment No. 4 (the "Amendment") to Schedule 13D amends the Schedule 13D filed by the Reporting Persons (defined below) with the SEC on July 5, 2017, as previously amended on August 22, 2018, March 18, 2019 and April 3, 2019 (the "Original Schedule 13D" and, together with the Amendment, the "Schedule 13D") and relates to the common stock, par value \$0.001 per share (the "Common Stock"), of Aileron Therapeutics, Inc., a Delaware corporation (the "Issuer"). The address of the Issuer's principal executive office is 490 Arsenal Way, Watertown, MA 02472.

As a result of the open market sales reported in Item 5(c) of this Amendment, the percentage of outstanding shares of Common Stock that the Reporting Persons may be deemed to beneficially own was reduced by more than one percent of the Issuer's shares of Common Stock outstanding since the filing of the Original Schedule 13D.

Except as otherwise described herein, the information contained in the Original Schedule 13D remains in effect. Capitalized terms used but not defined in this Amendment shall have the respective meanings set forth with respect thereto in the Original Schedule 13D.

Item 2. Identity and Background.

Item 2 of the Original Schedule 13D is hereby amended such that all references to Schedule I contained within Item 2 and otherwise within the Schedule 13D shall refer to the Schedule I included in this Amendment.

Item 3. Source and Amounts of Funds or Other Consideration.

No changes.

Item 4. Purpose of Transaction.

The information set forth in Item 5(c) of this Amendment is incorporated herein by reference. Otherwise, there are no changes to the disclosure provided under this Item 4 in the Original Schedule 13D.

Item 5. Interest in Securities of the Issuer.

(a) As of the date hereof, the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Act, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of 1,882,119 shares of Common Stock. NBV is a wholly-owned indirect subsidiary of Novartis. Based on 27,810,358 shares of Common Stock outstanding as of November 5, 2019, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on November 7, 2019, the Common Stock held by the Reporting Persons constitutes 6.77% of the outstanding shares of Common Stock of the Issuer.

(b) With respect to the number of shares of Common Stock as to which each Reporting Person has:

(i) sole power to vote or to direct the vote with respect to such shares of Common Stock, please see row 7 of the applicable cover sheet to this Amendment for such Reporting Person;

(ii) shared power to vote or to direct the vote with respect to such shares of Common Stock, please see row 8 of the applicable cover sheet to this Amendment for such Reporting Person;

(iii) sole power to dispose or direct the disposition of such shares of Common Stock, please see row 9 of the applicable cover sheet to this Amendment for such Reporting Person; and

(iv) shared power to dispose or to direct the disposition of such shares of Common Stock, please see row 10 of the applicable cover sheet to this Amendment for such Reporting Person.

(c) Other than the open market sales referred to below or previously reported in the Original Schedule 13D, none of (i) the Reporting Persons or, (ii) to the Reporting Persons' knowledge, the persons set forth on Schedule I hereto has effected any transaction in the Common Stock during the past 60 days.

On March 16, 2020, the Reporting Persons sold 8,995 shares of Common Stock at a weighted average price of \$0.28 per share (price range: \$0.27 - \$0.31).

On March 12, 2020, the Reporting Persons sold 10,932 shares of Common Stock at a weighted average price of \$0.33 per share (price range: \$0.25 - \$0.40).

On March 11, 2020, the Reporting Persons sold 16,759 shares of Common Stock at a weighted average price of \$0.42 per share (price range: \$0.38 - \$0.49).

On March 10, 2020, the Reporting Persons sold 9,400 shares of Common Stock at a weighted average price of \$0.48 per share (price range: \$0.47 - \$0.51).

On March 9, 2020, the Reporting Persons sold 17,392 shares of Common Stock at a weighted average price of \$0.51 per share (price range: \$0.48 - \$0.57).

On March 6, 2020, the Reporting Persons sold 13,301 shares of Common Stock at a weighted average price of \$0.55 per share (price range: \$0.54 - \$0.58).

On March 3, 2020, the Reporting Persons sold 41 shares of Common Stock at a price of \$0.65 per share.

On February 26, 2020, the Reporting Persons sold 6,603 shares of Common Stock at a weighted average price of \$0.65 per share (price range: \$0.64 - \$0.67).

On February 25, 2020, the Reporting Persons sold 24,316 shares of Common Stock at a weighted average price of \$0.68 per share (price range: \$0.64 - \$0.72).

On February 24, 2020, the Reporting Persons sold 10,146 shares of Common Stock at a weighted average price of \$0.70 per share (price range: \$0.69 - \$0.71).

On February 21, 2020, the Reporting Persons sold 13,800 shares of Common Stock at a weighted average price of \$0.72 per share (price range: \$0.70 - \$0.73).

On February 20, 2020, the Reporting Persons sold 15,000 shares of Common Stock at a weighted average price of \$0.70 per share (price range: \$0.70 - \$0.72).

On February 19, 2020, the Reporting Persons sold 14,900 shares of Common Stock at a weighted average price of \$0.70 per share (price range: \$0.68 - \$0.70).

On February 18, 2020, the Reporting Persons sold 35,690 shares of Common Stock at a weighted average price of \$0.70 per share (price range: \$0.67 - \$0.72).

The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Item 5(c).

(d) Not applicable.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

No changes.

Item 7. Material to be Filed as Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Agreement regarding joint filing of Schedule 13D

Signature

After reasonable inquiry and to the best of the undersigned's knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

Date: March 17, 2020

NOVARTIS BIOVENTURES LTD.

By: /s/ Bart Dzikowski

Name: Bart Dzikowski

Title: Secretary of the Board

By: /s/ Beat Steffen

Name: Beat Steffen

Title: Authorized Signatory

NOVARTIS AG

By: /s/ Bart Dzikowski

Name: Bart Dzikowski

Title: Authorized Signatory

By: /s/ Beat Steffen

Name: Beat Steffen

Title: Authorized Signatory

SCHEDULE I**DIRECTORS AND EXECUTIVE OFFICERS OF
NOVARTIS AG AND NOVARTIS BIOVENTURES LTD.***Directors and Executive Officers of Novartis AG*

The name, function, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis AG are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual's name refers to employment with Novartis AG and (ii) the business address of each director and executive officer of Novartis AG is Novartis Campus, Lichtstrasse 35, CH-4056, Basel, Switzerland.

Name	Relationship to Novartis AG	Present Principal Occupation	Citizenship
Joerg Reinhardt, Ph.D.	Chairman of the Board of Directors	Chairman of the Board of Directors	German
Enrico Vanni, Ph.D.	Vice Chairman of the Board of Directors	Independent Consultant	Swiss
Nancy C. Andrews, M.D., Ph.D.	Director	Dean Emerita of the Duke University School of Medicine and Vice Chancellor Emerita for Academic Affairs at Duke University; Professor of Pediatrics, Pharmacology and Cancer Biology at Duke University	American
Patrice Bula	Director	Executive Vice President and Head of Strategic Business Units at Nestlé SA; Chairman of the board at Nespresso SA	Swiss
Ton Buechner	Director	Independent Consultant	Dutch
Srikant Datar, Ph.D.	Director	Arthur Lowes Dickinson Professor at the Graduate School of Business Administration at Harvard University	American
Elizabeth (Liz) Doherty	Director	Non-executive director and chairman of the audit committee of Dunelm Group plc; Member of the Supervisory Board and Audit Committee of Corbion NV	British
Ann Fudge	Director	Vice Chairman and Senior Independent Director of Unilever NV	American
Bridgette Heller	Director	Co-founder and CEO, Shirley Proctor Puller Foundation	American

Name	Relationship to Novartis AG	Present Principal Occupation	Citizenship
Franz van Houten	Director	CEO and Chairman of the Executive Committee and the Board of Management of Royal Philips	Dutch
Simon Moroney	Director	Independent Consultant	German/New Zealand
Andreas von Planta, Ph.D.	Director	Senior Counsel at Lenz & Staehelin	Swiss
Charles L. Sawyers, M.D.	Director	Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center; Professor of Medicine and of Cell and Developmental Biology at the Weill Cornell Graduate School of Medical Sciences; Investigator at the Howard Hughes Medical Institute	American
William T. Winters	Director	CEO and a board member of Standard Chartered	British
Vasant (Vas) Narasimhan, M.D.	Member of the Executive Committee; Chief Executive Officer	Member of the Executive Committee, Chief Executive Officer	American
Steven Baert	Member of the Executive Committee; Head of Human Resources	Member of the Executive Committee, Head of Human Resources	Belgian
Susanne Schaffert, Ph.D.	Member of the Executive Committee; President, Novartis Oncology	Member of the Executive Committee; President, Novartis Oncology	German
Bertrand Bodson	Member of the Executive Committee; Chief Digital Officer	Member of the Executive Committee; Chief Digital Officer	Belgian
James (Jay) Bradner, M.D.	Member of the Executive Committee; President, Novartis Institutes for BioMedical Research	Member of the Executive Committee; President, Novartis Institutes for BioMedical Research	American
Klaus Moosemayer, Ph.D.	Member of the Executive Committee; Chief Ethics, Risk and Compliance Officer	Member of the Executive Committee; Chief Ethics, Risk and Compliance Officer	German

Name	Relationship to Novartis AG	Present Principal Occupation	Citizenship
Marie-France Tschudin	Member of the Executive Committee; President, Novartis Pharmaceuticals	Member of the Executive Committee; President, Novartis Pharmaceuticals	Swiss
Harry Kirsch	Member of the Executive Committee; Chief Financial Officer	Member of the Executive Committee; Chief Financial Officer	German
Shannon Thyme Klinger	Member of the Executive Committee; Group General Counsel	Member of the Executive Committee; Group General Counsel	American
Richard Saynor	Member of the Executive Committee; CEO, Sandoz	Member of the Executive Committee; CEO, Sandoz	British
Steffen Lang, Ph.D.	Member of the Executive Committee; Global Head of Novartis Technical Operations	Member of the Executive Committee; Global Head of Novartis Technical Operations	German
John Tsai, M.D.	Member of the Executive Committee; Head of Global Drug Development and Chief Medical Officer	Member of the Executive Committee; Head of Global Drug Development and Chief Medical Officer	American
Robert Weltevreden	Member of the Executive Committee; Head of Novartis Business Services	Member of the Executive Committee; Head of Novartis Business Services	Dutch

Directors and Officers of Novartis Bioventures Ltd.

The name, address, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis Bioventures Ltd. are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual's name refers to employment with Novartis Bioventures Ltd. and (ii) the business address of each director and executive officer of Novartis Bioventures Ltd. is Novartis Campus, Lichtstrasse 35, CH-4056, Basel, Switzerland.

Name	Relationship to Novartis Bioventures Ltd.	Present Principal Occupation	Citizenship
Prof. Dr. Patrick Aebischer	Chairman of the Board of Directors	President emeritus of the École Polytechnique Fédérale de Lausanne (EPFL); Senior Partner at NanoDimension-III Management.	Swiss
Michael Gilman, Ph.D.	Director	Chief Executive Officer and Chairman of the Board at Arrakis Therapeutics, Inc.	American
Harry Kirsch	Director	Member of the Executive Committee of Novartis; Chief Financial Officer at Novartis	German
Prof. Dr. Christoph Meier	Director	Chief Medical Officer at the University Hospital Basel; Professor at the Medical Faculty of the University of Geneva	Swiss
Dr. Elaine Jones	Director	Independent Consultant	American
James (Jay) Bradner, M.D.	Director	Member of the Executive Committee of Novartis; President, Novartis Institutes for BioMedical Research	American
John Tsai, M.D.	Director	Member of the Executive Committee of Novartis; Head of Global Drug Development and Chief Medical Officer at Novartis	American

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock beneficially owned by each of them of Aileron Therapeutics, Inc. This Joint Filing Agreement shall be included as an Exhibit to such Schedule 13D.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 17th day of March, 2020.

NOVARTIS BIOVENTURES LTD.

By: /s/ Bart Dzikowski

Name: Bart Dzikowski

Title: Secretary of the Board

By: /s/ Beat Steffen

Name: Beat Steffen

Title: Authorized Signatory

NOVARTIS AG

By: /s/ Bart Dzikowski

Name: Bart Dzikowski

Title: Authorized Signatory

By: /s/ Beat Steffen

Name: Beat Steffen

Title: Authorized Signatory